Thrombophilias often cause CRAO. 8, 10, 12, 15, 19, 23 In our recent study of 9 CRAO patients, 3 (33%) had low (<73%) protein C versus 2/37 controls (5%), P = .044 23 ; 2 had high (≥13.5 umol/L) homocysteine versus 0/42 controls (0%), P = .028 23 ; and 4 had the lupus anticoagulant (44%) versus 4/33 (12%) controls, P = .05. 23 In the absence of carotid atherosclerosis, thrombophilias often cause amaurosis fugax. 21 In our previous assessment 21 of 11 cases of amaurosis fugax without evidence of carotid plaque, all 11 cases had 1 or more familial coagulation disorders, including 1 and 2 PTG heterozygotes. The proband's 69-year-old father, with NAION and ischemic stroke, had PTG heterozygosity, familial high factor VIII, and compound MTHFR C677T-A1298C mutation with homocysteinemia. The proband's 61-year-old aunt had PTG heterozygosity, recurrent DVT, and mesenteric artery thrombosis. The proband's 67-year-old mother, free of thrombotic events, was a FVL heterozygote, had high factor VIII, and PAI-1 4G4G homozygosity. In this extended kindred, ocular thrombotic events (amaurosis fugax, NAION) were associated with variegated thrombotic events, including TIA, ischemic stroke, DVT, PE, and mesenteric artery thrombosis, and opened a diagnostic window to family screening and treatment for complex thrombophilias, which had previously been undiagnosed.
Introduction
Ocular thrombotic events, amaurosis fugax, central retinal artery occlusion (CRAO), nonarteritic ischemic optic neuropathy (NAION), and central retinal vein occlusion can be caused by thrombophilia-hypofibrinolysis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The diagnosis of an underlying thrombophilic-hypofibrinolytic etiology for ocular thrombotic events opens anticoagulant treatment avenues [20] [21] [22] and is important in prevention of other thromboses in the proband's firstdegree relatives.
In a 12-member, 3-generation kindred with conjoint inheritance of G1691A factor V Leiden (FVL) and G20210A prothrombin gene (PTG) mutations, identified through a proband with amaurosis fugax and his father with nonarteritic ischemic optic neuropathy (NAION), the authors' hypothesis was that ocular thrombosis was a diagnostic window to familial thrombophilia-thrombosis. The authors used polymerase chain reaction (PCR) measures for thrombophilia (FVL, PTG, C677T-A1298C methylenetetrahydrofolate reductase [MTHFR], platelet glycoprotein PLA1A2) and hypofibrinolysis (plasminogen activator inhibitor-1 4G4G). The 39-year-old white male proband, with amaurosis fugax and transient ischemic attacks (TIA), was found to be a compound heterozygote for FVL and PTG mutations. His symptoms resolved only after coumadin. His 44-year-old brother (deep venous thrombosis [DVT]) and 46-year-old sister (DVT, pulmonary embolus [PE]) were compound FVL-PTG gene heterozygotes. Of 4 asymptomatic children born to these 3 siblings, 2 were FVL heterozygotes factor V Leiden (FVL) heterozygote, 2 with low free protein S, 4 with high factor VIII, 3 with resistance to activated protein C, 3 homozygous for the C677T MTHFR mutation, 2 compound C677T-A1298C heterozygotes, and 3 with hypofibrinolytic 4G4G homozygosity for the PAI-1 gene. 21 Subsequently, in 19 patients with amaurosis fugax associated with heritable thrombophilia-hypofibrinolysis without ipsilateral atherosclerotic carotid plaque, we examined the hypothesis that case-specific thromboprophylaxis would prevent subsequent amaurosis fugax episodes. 24 We reported that within 1 month of starting thromboprophylaxis patients became asymptomatic and have remained asymptomatic for 1 or more years on therapy. 24 Our previous studies of 12 patients with NAION 17 revealed that patients with NAION were more likely than controls to demonstrate thrombophilic homozygosity for the C677T MTHFR mutation, 50% versus 11%, P = .0009. Moreover, of the 12 NAION patients, 7 had at least 1 mutation in the C677T MTHFR, FVL, or prothrombin (PTG) genes, compared with 5 of 36 controls (P = .002). 17 Similarly, Nagy et al 25 evaluated 37 NAION patients and 81 matched controls. High Lp(a), diabetes mellitus, and the FVL mutation were the main predictive components (P = .012, .022, .033). Randhawa and Van Stavern 26 have reported that NAION was associated with the sticky platelet syndrome in a 15-year-old boy. Srinivasan et al 20 reported that low-molecular-weight heparin followed by warfarin resulted in reversal of NAION in a woman with primary antiphospholipid syndrome and coexisting FVL mutation. However, Salomon et al, 27 in a retrospective case-control study of 61 patients with NAION, found that none of the thrombophilic markers (genetic and acquired) constituted a significant risk factor for NAION.
In a 3-generation kindred, identified through a 39-year-old Caucasian proband with amaurosis fugax, with 12 family members tested for conjoint inheritance of the FVL and PTG mutations, we assessed ocular thrombosis as a window to diagnosis of familial thrombophilia and thrombosis. Better understanding of associations between heritable thrombophilia, NAION, amaurosis fugax, and retinal artery occlusion should facilitate the surveillance, prevention, and treatment of ocular thrombotic events. 22, [28] [29] [30] [31] [32] The associations of ocular thrombotic events and familial thrombophilia also has broad clinical implications, because thrombophilia can cause preventable/ reversible deep vein thrombosis, 33 pulmonary embolism, 33 ischemic cerebral vascular accidents, 16 osteonecrosis, 34 Legg-Calve-Perthes disease, 35 and sporadic and recurrent pregnancy loss. 36, 37 
Methods

Setting, Study Design, and Patients
Informed consent was obtained after the nature of the procedures had been fully explained. The procedures followed were in accordance with the ethical standards of the institutional Review Board of the Jewish Hospital, Cincinnati, Ohio, which approved the research protocol.
One or more months after ocular thrombotic events, polymerase chain reaction (PCR) and serologic coagulation assays were done ( Figure 1 ). The proband (II-2, Figure 1 ) and his father (I-2, Figure 1 ) were receiving coumadin at the time of our evaluation. No other family member had taken coumadin or heparin within 3 months of blood sampling. At the subjects' initial visit, a detailed history and physical examination was carried out with a focus on cardiovascular events, hypertension, diabetes, pulmonary embolus (PE), deep venous thrombosis (DVT), reproductive history, estrogen-containing oral contraceptives, hormone replacement therapy, selective estrogen receptor modulators, and therapy for hypertension, diabetes, and hyperlipidemia.
Blood specimens for coagulation measures (Figure 1 ) were obtained between 8 and 10 AM after an overnight fast from seated patients as previously described. 16, 28, 29 All ocular diagnoses were made by the referring vitreoretinal specialists.
Amaurosis fugax was diagnosed by the development of transient monocular visual loss, with normal carotid and vertebral Doppler studies, associated with regional retinal pallor, microinfarcts, and small retinal hemorrhages. 38 NAION 39 was diagnosed by a history of painless monocular loss of vision, optic disc edema resolving optic disc pallor, a visual field defect, and exclusion of arteritic anterior ischemic optic neuropathy by history, examination, and sedimentation rate.
Controls
To assess the likelihood of compound FVL-PTG heterozygosity in healthy normal subjects, we carried out PCR analyses in 238 previously described normal controls. 40 Also, we assessed the likelihood of compound FVL-PTG heterozygosity in 2490 patients with coagulation disorders in our Cholesterol Center who had both FVL and PTG genes studied by PCR.
Polymerase Chain Reaction Assays
PCR measures were made of mutations associated with thrombophilia (FVL, PTG, MTHFR 1298C-C677T, platelet glycoprotein PLA1-A2), and hypofibrinolysis (plasminogen activator inhibitor-1 4G4G). Previously published methods were used by laboratory staff blinded to the subjects' status (patient, control, severity of patients). 28, 29, 36, 37, [40] [41] [42] 
Serologic Measures of Thrombophilia
Serologic measures of thrombophilia included anticardiolipin antibodies (IgG and IgM), antigenic protein C, total and free protein S, antithrombin III, the lupus anticoagulant, factors VIII and XI, and homocysteine. Established, previously published methods were used. 40, [42] [43] [44] 
Serologic Measures of Hypofibrinolysis
Serologic measures of hypofibrinolysis, Lp(a), and plasminogen activator inhibitor activity (PAI-Fx) were done using established, previously published methods. 29, 43, 44 
Statistical Methods
The likelihood of compound FVL-PTG heterozygosity in the kindred members versus 238 normal controls and versus 2490 patients being evaluated in our center for coagulation disorders was assessed by Fisher's exact test.
Results
The likelihood of having subjects in the kindred with compound FVL-PTG heterozygosity (3/12, 25%) was far higher than in healthy controls (0/238, 0%), Fisher's exact P < .0001, and was also far higher than in our patient population being evaluated for coagulation disorders (2/2490, 0.1%), Fisher's exact P < .0001. The likelihood of having subjects in the kindred with FVL heterozygosity without a concurrent PTG mutation (3/12, 25%) was higher than in healthy normal controls (7/238, 3%), Fisher's P = .0084. The likelihood of having subjects in the kindred with PTG heterozygosity without the FVL mutation (6/12, 50%) was higher than in healthy normal controls (9/238, 4%), Fisher's P < .0001. The 39-year-old white male proband (II-2, Figure  1 ) had amaurosis fugax and transient ischemic attacks (TIAs) and was found to be a compound heterozygote for the FVL and PTG mutations. Only after coumadin therapy did his symptoms resolve. His 44-year-old brother (history of DVT; II-3, Figure 1 ) and 46-yearold sister (DVT, PE; II-5, Figure 1 ) were also compound FVL-PTG heterozygotes. Of 4 asymptomatic children born to these 3 siblings, 2 were heterozygous for the FVL mutation (III-1 and III-2) and 2 (III-3 and III-4) were heterozygous for PTG mutation (Figure 1) . The proband's 69-year-old father (I-2, Figure 1 ) had NAION and ischemic stroke, was heterozygous for the PTG mutation, had high factor VIII, and had a compound MTHFR C677T-A1298C mutation with accompanying hyperhomocysteinemia. The proband's 61-year-old aunt (I-1, Figure 1 ) had PTG heterozygosity, recurrent DVT, and a history of mesenteric artery thrombosis. The proband's 67-year-old mother (I-3, Figure 1 ), free of thrombotic events, was heterozygous for the FVL mutation, had high factor VIII, and had hypofibrinolytic 4G4G homozygosity for the PAI-1 gene.
As displayed in Figure 1 , there was extensive 3-generation vertical and horizontal transmission of the FVL and PTG mutations. All compound FVL-PTG heterozygotes had sustained thrombotic events before age 50, including amaurosis fugax, TIA, DVT, and PE (Figure 1 ).
In this extended kindred, ocular thrombotic events (amaurosis fugax, NAION) were associated with variegated thrombotic events, including TIA, ischemic stroke, DVT, PE, and mesenteric artery thrombosis, and opened the diagnostic window to family screening and treatment for complex thrombophilias, which had previously been undiagnosed.
Discussion
Vossen et al 45 have assessed the likelihood of recurrence rate of venous thrombosis after a first venous thrombotic event in patients with familial thrombophilia attributable to FVL or deficiencies of proteins C, S, or AT III. Over a mean follow-up period of 5.6 years, 44 of 180 patients with familial thrombophilia who did not use long-term anticoagulation experienced a recurrent venous thromboembolic event (5% per year, 95% confidence interval 3.6% to 6.7%) compared with 7 of 124 patients on long-term anticoagulation (1.1% per year, 95% confidence interval 0.4% to 2.2%). Spontaneous events occurred less often in patients on long-term anticoagulation (57% of patients) than in patients without anticoagulation (75% of patients). 45 The highest recurrence rate of venous thrombosis was found in men with a deficiency of natural anticoagulants or multiple defects. 45 Although long-term anticoagulation treatment decreased the incidence of recurrent events by 80%, it also resulted in a risk of major hemorrhage of 0.8% per year. 45 Coinheritance of the 20210A allele of the PTG gene increases the already higher risk of thrombosis in subjects with familial thrombophilia, [45] [46] [47] [48] [49] and, as in the current kindred, the risk of thrombosis is further amplified by the presence of other thrombophilias. 49 Friedline et al 49 studied FVL and PTG mutations in 401 patients presenting with thromboembolic disease, of whom 8% were heterozygous for FVL, 1% homozygous for FVL, 5% heterozygous for the PTG mutation, and 2 (0.5%) had combined FVL and PTG mutations. Ehrenforth et al 50 have reported that the A20210 allele of the PTG gene is significantly overrepresented in symptomatic FVL heterozygotes compared with healthy controls (P < .0001) and asymptomatic relatives carrying the FV mutant (P = .02). Moreover, as was the case in our kindred, Ehrenforth et al 50 reported that there was an increase in the prevalence of more unusual sites of venous thrombosis at clinical onset in compound FVL-PTG heterozygotes (9 of 30, 30%) compared with patients without the PTG mutation (26 of 233, 11.1%), P = .004. 50 The first VTE occurred spontaneously in 53.3% of compound FVL-PTG heterozygotes (16 of 30) and in 28.3% of patients with a single FVL or PTG mutation (66 of 233), P = .005. 50 Ehrenforth et al 50 concluded that the A20210 allele of the PTG gene was frequently coinherited in symptomatic FVL heterozygotes and influenced the age, site, and type of thrombotic onset manifestation in these patients, as it did in the current report. However, compound heterozygosity for FVL and PTG may not necessarily be associated with increased risk of thrombosis beyond a single thrombophilic gene mutation. 47, 51 Documentation of pathoetiologic coagulation disorders 22,28-31,52-57 may also be important for prevention of NAION or amaurosis in the contralateral eye. The presence of multiple coagulation disorders, as in both amaurosis fugax and NAION in the present study, promotes ocular thrombosis, 22, 58 which can lead to acute decompensation of the blood supply to the optic disc. 32 In central retinal venous occlusion 22 as well as in CRAO-amaurosis fugax, 21 diagnosis of pathoetiologic thrombophilia-hypofibrinolysis is important because, as concluded by Bick et al, 22 "it allows for definition of appropriate acute antithrombotic therapy and subsequent thromboprophylaxis to prevent additional visual loss and also allows identification of those patients with thrombophilias so other thrombotic events can be avoided and appropriate family members assessed when clinically warranted." Particularly in the presence of thrombophilia-hypofibrinolysis, 22 potentially reversible 32,59-62 thrombosis often leads to irreversible visual loss.
